Argent BioPharma Ltd. Placing to Raise US$4,500,000
Argent BioPharma (ASX: RGT) (OTCQB: RGTLF) has successfully completed a US$4.5 million capital raise through a placement of 5,625,000 Units at US$0.80 each. Each Unit includes two ordinary shares and one warrant exercisable at US$0.55 with a three-year expiry.
The placement will be executed in two tranches: Tranche 1 with 5,000,000 shares and 2,500,000 warrants issued immediately, and Tranche 2 with 6,250,000 shares and 3,125,000 warrants pending shareholder approval. The placement shares are priced at US$0.40, representing a 370% premium to the 15-day VWAP.
The funds will support Argent's drug development pipeline, particularly CannEpil® clinical studies. The company is conducting a strategic review following LSE delisting and preparing for US National Listing. Sputnik Enterprises , acting as corporate advisor, will receive a 5% cash fee and 1,125,000 warrants.
Argent BioPharma (ASX: RGT) (OTCQB: RGTLF) ha recentemente completato con successo un aumento di capitale di 4,5 milioni di dollari USA attraverso una collocazione di 5.625.000 Unità a 0,80 dollari USA ciascuna. Ogni Unità include due azioni ordinarie e un warrant esercitabile a 0,55 dollari USA con scadenza di tre anni.
Il collocamento sarà eseguito in due tranche: Tranche 1 con 5.000.000 di azioni e 2.500.000 di warrants emessi immediatamente, e Tranche 2 con 6.250.000 di azioni e 3.125.000 di warrants in attesa di approvazione da parte degli azionisti. Le azioni del collocamento sono prezzate a 0,40 dollari USA, rappresentando un premio del 370% rispetto al VWAP di 15 giorni.
I fondi supporteranno il pipeline di sviluppo di farmaci di Argent, in particolare gli studi clinici su CannEpil®. L'azienda sta conducendo una revisione strategica dopo la cancellazione dalla LSE e si sta preparando per la registrazione nazionale negli Stati Uniti. Sputnik Enterprises, in qualità di consulente aziendale, riceverà una commissione in contanti del 5% e 1.125.000 warrants.
Argent BioPharma (ASX: RGT) (OTCQB: RGTLF) ha completado con éxito una recapitalización de 4,5 millones de dólares estadounidenses a través de la colocación de 5.625.000 Unidades a 0,80 dólares cada una. Cada Unidad incluye dos acciones ordinarias y una garantía que puede ejercerse a 0,55 dólares con una fecha de caducidad de tres años.
La colocación se llevará a cabo en dos tramos: Tramo 1 con 5.000.000 de acciones y 2.500.000 de garantías emitidas de inmediato, y Tramo 2 con 6.250.000 de acciones y 3.125.000 de garantías pendientes de la aprobación de los accionistas. Las acciones de la colocación tienen un precio de 0,40 dólares, lo que representa una prima del 370% sobre el VWAP de 15 días.
Los fondos respaldarán la cartera de desarrollo de fármacos de Argent, especialmente los estudios clínicos de CannEpil®. La empresa está llevando a cabo una revisión estratégica tras su exclusión de la LSE y se está preparando para la cotización nacional en EE.UU. Sputnik Enterprises, actuando como asesor corporativo, recibirá una tarifa en efectivo del 5% y 1.125.000 garantías.
아르헨트 바이오파마 (ASX: RGT) (OTCQB: RGTLF)는 450만 달러의 자본 증가를 성공적으로 완료하였습니다. 이번 증자는 각각 0.80달러에 5,625,000 유닛을 배치하는 것입니다. 각 유닛에는 두 개의 보통주와 0.55달러에 행사 가능한 한 개의 워런트가 포함되어 있으며, 만기는 3년입니다.
이번 증자는 두 단계로 진행됩니다: 1단계는 5,000,000 주와 즉시 발행되는 2,500,000 워런트, 2단계는 6,250,000 주와 3,125,000 워런트가 주주 승인을 기다리고 있습니다. 배정된 주식의 가격은 0.40달러로, 최근 15일 평균 거래 가격에 비해 370%의 프리미엄을 나타냅니다.
이번 자금은 아르헨트의 약물 개발 파이프라인, 특히 CannEpil®의 임상 연구를 지원할 것입니다. 회사는 LSE 상장 폐지 이후 전략적 검토를 진행 중이며 미국 국가 상장을 준비하고 있습니다. 기업 자문 역할을 하는 스푸트니크 엔터프라이즈는 5%의 현금 수수료와 1,125,000 워런트를 받게 됩니다.
Argent BioPharma (ASX: RGT) (OTCQB: RGTLF) a réussi à réaliser une levée de fonds de 4,5 millions de dollars américains grâce à un placement de 5.625.000 unités à 0,80 dollar chacune. Chaque unité comprend deux actions ordinaires et un bon de souscription exerçable à 0,55 dollar avec une durée de trois ans.
Le placement se fera en deux tranches : Tranche 1 avec 5.000.000 d’actions et 2.500.000 de bons de souscription émis immédiatement, et Tranche 2 avec 6.250.000 d’actions et 3.125.000 de bons de souscription en attente de l'approbation des actionnaires. Les actions du placement sont au prix de 0,40 dollar, ce qui représente une prime de 370 % par rapport à la VWAP sur 15 jours.
Les fonds soutiendront le pipeline de développement de médicaments d'Argent, en particulier les études cliniques sur CannEpil®. L'entreprise effectue une révision stratégique suite à sa radiation de la LSE et se prépare à une cotation nationale aux États-Unis. Sputnik Enterprises, agissant en tant que conseiller corporate, recevra des frais en espèces de 5 % et 1.125.000 bons de souscription.
Argent BioPharma (ASX: RGT) (OTCQB: RGTLF) hat erfolgreich eine Kapitalerhöhung von 4,5 Millionen US-Dollar durch die Platzierung von 5.625.000 Einheiten zu je 0,80 US-Dollar abgeschlossen. Jede Einheit umfasst zwei Stammaktien und einen Warrant, der zu 0,55 US-Dollar mit einer Laufzeit von drei Jahren ausgeübt werden kann.
Die Platzierung wird in zwei Tranchen durchgeführt: Tranche 1 mit 5.000.000 Aktien und sofort ausgegebenen 2.500.000 Warrants sowie Tranche 2 mit 6.250.000 Aktien und 3.125.000 Warrants, die auf die Genehmigung der Aktionäre warten. Die Platzierungsaktien werden zu 0,40 US-Dollar angeboten, was einen Aufschlag von 370 % gegenüber dem 15-tägigen VWAP darstellt.
Die Mittel werden die Arzneimittelentwicklungspipeline von Argent unterstützen, insbesondere die klinischen Studien zu CannEpil®. Das Unternehmen führt eine strategische Überprüfung nach der Delistung von der LSE durch und bereitet sich auf die nationale Zulassung in den USA vor. Sputnik Enterprises, der als Unternehmensberater fungiert, erhält eine Barvergütung von 5 % und 1.125.000 Warrants.
- Successfully raised US$4.5 million through placement
- Shares issued at 370% premium to 15-day VWAP
- Progress toward US National Listing
- Delisting from LSE
- Dilution of existing shareholders through new share issuance
- Additional dilution potential from warrant exercise
The company announces the successful completion of a
The Placement will be conducted in two tranches: Tranche 1: 5,000,000 Placement Shares and 2,500,000 Warrants to be issued immediately, utilising the Company's existing placement capacity under ASX Listing Rules 7.1 and 7.1A. Tranche 2: 6,250,000 Placement Shares and 3,125,000 Warrants to be issued subject to shareholder approval at an upcoming general meeting.
The Placement Shares will be issued at a price of
The proceeds from the Placement will support the advancement of Argent BioPharma's drug development pipeline, with a particular focus on progressing CannEpil® and its planned clinical studies.
The Company is also conducting a comprehensive strategic review of its operational and administrative functions to ensure the long-term sustainability of its operations, which is following the delisting from the LSE and establishing the work-plan toward US National Listing.
Corporate Advisor: Sputnik Enterprises Ltd acted as the corporate advisor for the Placement and will receive: A cash fee of
Authorised for release by the board of directors, for further information please contact:
Argent BioPharma
Roby Zomer
CEO & Managing Director
+61 8 6555 2950
info@argentbiopharma.com
Argent BioPharma
Rowan Harland
Company Secretary
+61 8 6555 2950
info@argentbiopharma.com
About Argent BioPharma
Argent BioPharma Limited (the "Company") (ASX: RGT);(OTCQB: RGTLF) is an innovative clinical-stage biopharmaceutical company specializing in neuroimmunology, developing advanced nano-medicines to address unmet medical needs in central nervous system (CNS) disorders and immune-related conditions. By leveraging cutting-edge technologies, including the Neuro-Immune Modulatory (NIM) System and its role in coordinating nervous and immune responses, Argent BioPharma's robust pipeline—featuring lead candidates like CannEpil®, CogniCann®, and CimetrA®—targets complex diseases where effective treatments are lacking. Through a commitment to science-driven innovation and patient-centered outcomes, Argent BioPharma is reshaping the future of care for chronic, inflammatory, and neurodegenerative diseases
Follow us through our social media channels:
LinkedIn: Argent BioPharma
Twitter: @ArgentBioPharma
Facebook: Argent BioPharma
View original content:https://www.prnewswire.com/news-releases/argent-biopharma-ltd-placing-to-raise-us4-500-000--302343111.html
SOURCE Argent BioPharma Ltd.
FAQ
How much did Argent BioPharma (RGTLF) raise in their January 2025 placement?
What is the structure of RGTLF's January 2025 placement units?
What premium does RGTLF's placement price represent to market?
How will RGTLF use the proceeds from the January 2025 placement?
What are the terms of Sputnik Enterprises' advisory fee for RGTLF's placement?
